Loss of heterozygosity (LOH) has been frequently detected at chromosome 7q31 region in human head and neck squamous cell carcinomas (HNSCC) and many other cancers, suggesting the existence of tumor suppressor genes (TSG). We analysed LOH at 7q31 region in 49 HNSCC by using six polymorphic microsatellite markers and found allelic deletion in 48% (22/46) of the informative cases. We detected two preferentially deleted regions, one is around D7S643 and the other around D7S486. When we rede®ned the map of 7q31 region according to the contiguous sequences, a recently identi®ed gene, ING3, was found in the proximity of D7S643. ING3 protein harbors the PHD domain highly homologous among ING family proteins, in which we previously found mutations in a related gene, ING1. As only one missense mutation of the ING3 gene was found in HNSCC, we examined the expression level. Reverse-transcription-PCR analysis demonstrated decreased or no expression of ING3 mRNA in 50% of primary tumors as compared with that of matched normal samples. Especially, about 63% of tongue and larynx tumors showed the decrease and a tendency of higher mortality was observed in cases with decreased ING3 expression. All these ®ndings suggest a possibility that the ING3 gene functions as a TSG in a subset of HNSCC.
Introduction
Tumor suppressor genes (TSG) are de®ned as genetic elements whose loss or mutational inactivation allows cells to acquire neoplastic growth (Hinds and Weinberg, 1994) . Cytogenetic studies have shown frequent chromosome 7 abnormalities in human head and neck squamous cell carcinomas (HNSCC) (Cowan et al., 1992) . Microcell-mediated transfer of human chromosome 7 into a murine squamous cell carcinoma cell line (Zenklusen et al., 1994) , or into a highly aggressive human prostate carcinoma cell line (Zenklusen et al., 2000) , inhibited the tumorigenicity of these cell lines. Similarly, insertion of an intact human chromosome 7 into an immortalized human ®broblast cell line with 7q31-32 deletion suppressed the immortality of the cells and restored their ability to senescence (Ogata et al., 1993) . All these studies provided some clues for the existence of a TSG(s) or a senescence-related gene(s) on chromosome 7.
Loss of heterozygosity (LOH) analysis by using polymorphic microsatellite markers is a sensitive method to detect micro-deletions. Frequent LOH in a chromosomal region is considered as an indication of the presence of a putative TSG (Knudson, 1993; Lin et al., 1996) . Recent studies have shown the frequent LOH at chromosomal region 7q31 in HNSCC (Zenklusen et al., 1995; Wang et al., 1998) , and also in various types of human cancers including breast, prostate, colon, ovary, thyroid and renal cell carcinomas (Latil et al., 1995; Takahashi et al., 1995; Zenklusen et al., 1995; Lin et al., 1996; Shridhar et al., 1997; Bieche et al., 1997; Zhang et al., 1998; Edelson et al., 1997) . In this study, we examined the 7q22-31 region by using a set of highly polymorphic microsatellite markers to ®nd out allelic loss in HNSCC. In the light of LOH analysis, we rede®ned the map of chromosome 7q31 region and examined some genes on this region by analysing mutation and mRNA expression. The results suggested that the ING3 gene is a likely candidate for one of the TSGs at 7q31. The prototype of the ING family gene, ING1, has been inferred for possible TSG function (Garkavtsev et al., 1996) and we have recently found allelic loss and tumor-speci®c mutations of the gene in HNSCC .
Results

LOH analysis
We examined LOH using six microsatellite markers on the chromosome 7q22-31 region in 49 paired normal and HNSCC DNAs. Overall, 48% (22/46) samples showed LOH at least one marker on 7q31. Figure 1a summarizes the results of LOH analyses. We detected two distinct regions of deletion. Markers D7S643 and D7S486 showed the highest incidence of LOH with a value of 35%, while¯anking markers demonstrated lower frequency. Five tumors (samples 18, 24, 34, 38 and 49) showed a deletion around the marker D7S643, while ®ve tumors (samples 8, 20, 21, 23 and 41) displayed a deletion preferentially around the marker D7S486. Seven tumors (samples 16, 26, 32, 39, 43, 47 and 48) demonstrated comparatively wide deletion including both of the above markers. Interestingly, three tumors (samples 7, 37 and 45) showed deletions around both markers D7S643 and D7S486 in spite of retaining another marker D7S522, which locates in between the former two markers. These results indicated that two dierent deleted regions were mapped to the vicinity of the markers D7S643 and D7S486, respectively. Representative examples of LOH are shown in Figure 1b .
Mapping of chromosome 7q31 region
Most of the chromosome 7 region has been sequenced and contiguous sequence results are available through the genome database on National Human Genome Research Institute home page (http://genome.nhgri.-nih.gov/chr7/). We searched the database and rede®ned the map of this region including the microsatellite markers that we used for LOH analysis as shown in Figure 2 . Our data pointed out a region around marker D7S643 as one of hot locations for TSG. The ING3 gene, a novel member of the ING family, of which cDNA sequence was recently identi®ed but yet published (GeneBank accession number: AF074968 and NM_019071, with an annotation made by Kawabata et al.) was found to be very close to the marker D7S643. The ING3 gene resides within 100 kbp to the marker D7S643, and it seemed that no other candidate TSG exists in this region.
Characterization of the human ING3 gene
One PAC clone (GeneBank accession number: AC004537) included the genomic DNA covering the entire region of the ING3 gene. When the amino acid sequence of the ING3 gene product, a putative 47 kDa protein (418 amino acids), was aligned with other four members of ING family proteins so far known, ING3 showed high homology with other members especially within PHD zinc ®nger domain and weak homology over the whole sequence particularly with ING1-p47 ( Figure 3 ). Of these sequences, only ING1 and ING2 (ING1L) were published (Garkavtsev et al., 1996; Shimada et al., 1998; Nagashima et al., 2001) . As some tumor speci®c mutations we previously reported are located in the PHD domain of ING1 protein , the potential important role of PHD domain has to be noticed commonly on the ING family proteins. The ING3 gene was composed of at least 12 exons spanning over 25 kb genomic interval ( Figure 4a ). To analyse the promoter for the ING3 gene, the 5' flanking 1.5 kb region including 5'-noncoding region of exon 1 was subcloned in sense or antisense orientation (Figure 4b ). Luciferase construct in sense orientation showed about 213-fold increase in luciferase activity as compared with the promoterless luciferase plasmid, while activity of luciferase construct in antisense orientation was not detectable. We searched for binding sites for transcription factors on this 1.5 kb promoter region, and found some binding motifs for factors such as Oct1, STAT, CREB and E2F ( Figure 4b) .
As revealed by Northern blot analysis (Figure 4c ), about 1.9 kb of ING3 transcript was detected in human heart, skeletal muscle, thymus, spleen, kidney, liver, placenta and peripheral blood leukocytes. ING3 mRNA expression in brain, colon, small intestine and lung was below the detectable level. We also found an alternatively spliced form of the ING3 message by cDNA cloning from human normal tissues. This variant form was devoid of the exon 3 but the coding frame was not shifted (data not shown).
Mutation analysis
We examined all exons of the ING3 gene for mutation analysis by PCR-SSCP (single-strand DNA conformational polymorphism) and direct sequencing in 49 HNSCC and four tumor-derived cell lines. We detected a tumor speci®c missense mutation in one sample and a silent change in three samples (data not shown). Sample 41 demonstrated a nucleotide change from GAC to GGC at codon 20 with an amino acid Since normal samples corresponding to these tumors also showed the same silent change, this was considered as a polymorphism.
ING3 mRNA expression analysis
Since mutation in this gene was very rare, we looked for other possible inactivation mechanisms. For this aim, we analysed the expression level of ING3 mRNA in tumor samples comparing with the paired normal tissue. In 40 available matched RNA samples, the expression levels of ING3 mRNA were compared by quantitative RT ± PCR using glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA as a control ( Figure  5 and Table 1 ). PCR primers were designed to encompass the exon/intron junctions on the cDNA in order to eliminate the potential contamination of genomic DNA. 
Discussion
We examined LOH at chromosome 7q22-31 region in 49 HNSCC by using six microsatellite markers. We found the deletions at 7q31 in almost half of the HNSCC samples (48%), while this value was lower than those of two previous reports in HNSCC with 56% and 67% LOH, respectively (Zenklusen et al., 1995; Wang et al., 1998) , probably because the specimens we used were not micro-dissected. In this study, however, we detected two distinct deletion regions around the markers D7S643 and D7S486, which is telomeric and centromeric to the marker D7S522, respectively. Although most tumors showed a comparatively wide deletion from D7S643 to D7S486, three tumors demonstrated two dierent deleted regions around the markers D7S643 and D7S486 but retaining an intact region between them. This suggests that there may be two dierent TSGs for HNSCC in this region. The region of 7q31, including D7S486 to D7S480 markers, has been focused as a hot location for LOH in many types of human cancer (Zenklusen et al., 1995; Wang et al., 1998; Latil et al., 1995; Takahashi et al., 1995; Bieche et al., 1997) . Edelson et al. (1997) reported two dierent regions with high incidence of LOH, one was around D7S643 and the other around D7S522 in ovarian cancers, similar to our results. Thus, deletions at 7q31 region appear to be Based on the recent human genome information, we rede®ned this region and mapped the ING3 gene, a novel member of the ING family, within one of the two peak areas of LOH we found. We therefore examined mutations in all exons of the ING3 gene in 49 HNSCC samples to investigate whether it is the target of functional loss in tumors. One tumor-speci®c missense mutation and three silent changes were detected. This missense mutation caused an amino acid change from aspartic acid to glycine at the N-terminal portion of ING3 protein. Although we do not know the importance of this mutation yet, it may exert an important change in structure and function of the protein.
Since ING3 mutation was very rare in our study, there may be other inactivation mechanisms. In facts, analyses of ING3 mRNA showed the decreased expression in 50% of primary tumors and 75% of tumor derived cell lines. Particularly, two primary tumors exhibited complete loss of the ING3 mRNA expression. Many of the other tumor samples showed less than half level of mRNA expression as compared with that of normal samples, though the expression level in tumor was not completely associated with LOH.
We could not ®nd any signi®cant correlation between clinicopathological features and expression levels of the ING3 gene except for tumor location. Majority of tongue and larynx cancers displayed decreased ING3 expression while only a small subset of oropharynx and hypopharynx cancers showed a decrease. We noticed a tendency toward earlier death in patients with tumor showing lower ING3 mRNA expression. This result suggests the potential prognostic signi®cance of the ING3 gene and also supports the possible tumor suppressor character of the gene. Further analysis with more samples at dierent locations may make this point clear.
Rare mutation but a considerably decreased expression of the ING3 gene suggests that the downregulation of this gene by transcriptional mechanism, such as promoter methylation, is an important step for carcinogenesis. We recently reported a high incidence of LOH and tumor-speci®c somatic mutations of the ING1 gene located on chromosome 13q34. One ING1 allele was deleted in 49% of HNSCC, although the incidence of the ING1 mutation was only 13% in HNSCC .
ING proteins belong to a family of proteins containing the plant homeodomain (PHD) ®nger, which includes transcription factors and proteins that regulate chromatin structure. Although the exact mode of action of ING proteins is yet to be known, several reports suggested that ING proteins may aect the activity of p53. ING1 proteins have at least four splicing variants and one of the variants, which is physically associated with p53, inhibits cell cycle progression (Garkavtsev et al., 1998) . ING2 protein negatively regulates cell proliferation and survival in a p53-dependent manner through induction of the G1 phase cell-cycle arrest and (Nagashima et al., 2001) . Furthermore, ING1 and ING2 proteins are associated with histone acetyltransferase activities (Loewith et al., 2000; Nagashima et al., 2001) . Actually, one of the spliced forms of ING1 is functionally associated with histone deacetylase (HDAC)-dependent transcriptional repression, in reporter gene expression assays in vivo, and in histone deacetylation assays in vitro (Skowyra et al., 2001) . Moreover, recent analysis of mouse Ing1 gene on structure and function suggested that a smaller isoform of ING1 protein, the mouse equivalent of human p24ING1c, is required for the activation of p53-responsive genes, in contrast, overexpression of the larger form, an equivalent of the human p33ING1b protein, interferes the activation of p53-dependent promoters when p53 is stabilized after DNA damage (Zeremski et al., 1999) . In fact, our analysis of ING1 mRNA expression demonstrated that one of the spliced form (p24ING1c) was reduced in most tumor tissues, while the other major variant (p33ING1b) showed variable expression in dierent tumors. However, when the expression of p33ING1b was reduced, p24ING1c was almost always decreased (Gunduz et al., unpublished data) . Toyama et al. (1999) reported that the ING1 gene showed decreased expression in 44% of tumors compared with matched normal samples, while 23% of tumors demonstrated increased expression in 377 primary breast cancers, although only one germ line missense mutation was found. It seems likely that isoforms of ING1 protein as well as dierent members of the ING family proteins may have dierent roles in growth control and that their unique N-terminal sequences may be implicated in the dierence. Thus, the inter-relationship among ING family proteins are complicated and may aect the expression of each other. Further functional studies are warranted to elucidate the exact relationship among ING family members and their individual and combined eects on cell growth. We compared the LOH status at both ING1 and ING3 loci in each HNSCC specimen. Interestingly, 73% of informative cases with LOH at the ING1 region also showed deletion at the ING3 region (data not shown). Concomitant deletion of both of the two genes in many HNSCC samples may lead to the haploid insuciency in respect to the levels of ING family proteins even without inactivating mutations or gene silencing. So far, some genes were proposed as candidate TSGs at 7q31 region. Hurlstone et al. (1999) reported mapping of the Caveolin-1 gene, a membrane-bound signaling mediator (Wary et al., 1996) , in the proximity of the marker D7S522 on 7q31. However, they found neither mutations nor methylation at the promoter region of the Caveolin-1 gene in both primary cancers and tumor cell lines. Genetic alterations of the PPP1R3 gene, encoding the regulatory subunit 3 of protein phosphatase 1 located at 7q31, have been reported in nine cell lines from various types of human cancers (Kohno et al., 1999) . Therefore, PPP1R3 has been considered as a candidate TSG in this region. However, when we determined the precise map position of the PPP1R3 gene, the BAC clone harboring the gene was located about 4 MB apart from the marker D7S486 ( Figure  2 ), which may be outside the consensus LOH area in HNSCC.
A recently identi®ed gene, TESTIN, was proposed as a candidate TSG at 7q31 region (Tatarelli et al., 2000) . They detected three missense mutations of the gene. Lack of expression was observed in 22% of cancer cell lines and 44% of cell lines derived from hematological malignancies, while TESTIN mRNA was expressed in all normal tissues. As D7S486 marker is located in the intron 6 of this gene, the targeted gene in the LOH area around D7S486 detected in our study may correspond to the TESTIN gene. Another novel TSG candidate gene, ST7, has recently been identi®ed at 7q31.1 (Zenklusen et al., 2001) . Six mutations of the gene were found in breast tumors and primary colon carcinomas. Sequence-based mapping of the ST7 gene revealed that the gene resides in between the markers D7S522 and D7S643, but much closer to the former (Figure 2 ). Since the incidence of LOH at D7S522 was signi®cantly lower than that at D7S643 in HNSCC (Figure 1a) , we suppose that the ST7 does not play an important role in the development of HNSCC.
Finally, our study suggested the ING3 gene as a candidate TSG at 7q31 region with considerable supporting ®ndings at least in cases of HNSCC. In the light of this study and previous reports, further works on these candidate genes with more samples of various types of human cancers are required to elucidate their roles in human carcinogenesis.
Materials and methods
Tissue samples
Paired normal and tumor samples were obtained from 49 patients with primary HNSCC at the Department of Otolaryngology Okayama University Hospital after acquisition of written informed consent from each patient. All tissues were frozen in liquid nitrogen immediately after surgery and stored at 7808C until the extraction of DNA and RNA.
Cell lines
HNSCC cell lines, SCC-KN and SCC-TF, derived from tongue tumor, T3M-1, derived from oral cavity tumor and HSQ-89, derived from maxillary sinus tumor, were purchased from Riken cell bank (Tsukuba, Japan).
DNA and RNA extraction
Genomic DNAs were isolated from frozen tissues by SDS/ proteinase K treatment, phenol-chloroform extraction, and ethanol precipitation. Total RNAs were prepared by using a modi®ed acid guanidinium phenol chloroform method (ISOGEN; Nippon Gene Co., Tokyo, Japan).
Microsatellite analysis
Primers for ampli®cation of microsatellite markers D7S480, D7S643, D7S522, D7S486, D7S525 and D7S1799 are available through the internet genome database (http:// gdbwww.gdb.org/). PCR ampli®cation was carried out in 20 ml of reaction mixture as described . Initial denaturation at 948C for 3 min was followed by 25 cycles of a denaturation step at 948C for 30 s, an annealing step at 548C (D7S1799, D7S525 and D7S486) or 608C (D7S522, D7S643 and D7S480) for 30 s, and an extension step at 728C for 1 min. A ®nal extension step at 728C for 7 min was added. After ampli®cation, 2 ml of the reaction mixture was electrophoresed through an 8% polyacrylamide gel containing 8 M urea. The DNA bands were visualized by silver staining (Bassam et al., 1991) . LOH was scored if one of the heterozygous alleles showed at least 50% reduced intensity in tumor DNA as compared with that of the corresponding normal DNA.
RT ± PCR analysis
Total RNA was reverse-transcribed with the SuperScript Preampli®cation System (Gibco BRL, Grand Island, NY, USA) starting with 3 mg of total RNA from each sample, according to the procedures provided by the supplier. One ml of each RT reaction was ampli®ed in 50 ml mixture containing 1. Appropriate cycling number for non-saturating measure was determined empirically by a quantitative PCR system (ABI GeneAmp 5700, Applied Biosystems). PCR ampli®cation was done essentially as described in microsatellite analysis, except that the annealing step was at 608C for 1 min.
Quantitation of the RT ± PCR products PCR products were separated through 2% agarose gel and stained with ethidium bromide. The size of the PCR products was 456 bp for GAPDH and 703 bp for ING3. The intensity of ethidium bromide staining of each band was measured by a CCD image sensor (Gel Print 2000/VGA, Toyobo, Osaka, Japan), and analysed by a computer program for band quanti®cation (Quantity One, Toyobo). The value of tumorspeci®c ING3 expression was determined by calculating the ratio of the expression level in the tumor and that in the matched normal sample, each of which was normalized for the corresponding GAPDH expression level. Decreased and increased expression levels were de®ned when this ratio was less than 0.6 and greater than 1.4, respectively. Reproducibility was con®rmed by independent PCR repeated twice.
Luciferase assay
Putative promoter region including the 5'-noncoding region of exon 1 was inserted in the promoterless luciferase plasmid pOA-luciferase (Kukita et al., 1999) in either sense or antisense orientation to produce reporter plasmids for the luciferase assay. Each reporter plasmid (0.5 mg) was cotransfected with 0.25 mg of an internal control Renilla luciferase plasmid, pRL-TK (Promega, Madison, WI, USA), into 293 human embryonic kidney cells using the calcium phosphate coprecipitation method. Cells were harvested 48 h after transfection. The activities of ®re¯y and Renilla luciferase were measured simultaneously using the Dual-Luciferase Reporter Assay kit (Promega) and normalized for the variation in transfection eciency. These assays were repeated twice in duplicate.
Northern blot analysis
Northern blot analysis was done according to the standard procedure (Tanino et al., 1999) on a nylon membrane with 2 mg of poly(A + ) mRNA (human MTN blot; Clontech) using a-32 P-dCTP-labeled ING3 cDNA as a probe. After hybridization, the ®lter was exposed to an imaging plate for image analyser BAS2000 (Fuji Film, Tokyo, Japan). The ®lter was rehybridized with another probe for GAPDH as an internal control.
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